Table 2. Survival according to MAPKBP1 expression in all patients and European Leukemia Net Genetic Groups.
| Outcome | All patients, n=157 | ELN Favorable group | Intermediate-I | ||||||
|---|---|---|---|---|---|---|---|---|---|
| MAPKBP1high, n=78 | MAPKBP1low, n=79 | P | MAPKBP1high, n=19 | MAPKBP1low, n=40 | P | MAPKBP1high, n=68 | MAPKBP1low, n=54 | P | |
| OS | |||||||||
| Median OS, m | 10.46 (0.07-198.7) |
43.47 (0.13-214.5) |
0.00 7 |
20.01 (1.05-163.10) |
52.28 (0.3-214.5) |
0.2 7 |
8.49 (0.07-198.7) |
39.54 (0.13-190.3) |
0.04 |
| Estimated OS at 3 y. % (95% CI) | 0.29 (0.21-0.42) |
0.58 (0.48-0.70) |
0.01 | 0.42 (0.25-0.71) | 0.63 (0.49-0.80) |
0.1 9 |
0.264 (0.18-0.4) |
0.56 (0.44-0.71) |
0.04 |
| EFS | |||||||||
| Median EFS, m | 7.64 (0.03-198.7) |
28.12 (0.03-214.5) |
0.00 4 |
11.93 (0.03-131.9) |
40.48 (0.03-214.5) |
0.2 1 |
6.83 (0.03-198.7) |
24.94 (0.03-190.3) |
0.00 9 |
| Estimated EFS at 3 y. % (95% CI) | 0.23 (0.15-0.35) |
0.46 (0.36-0.58) |
0.00 2 |
0.37 (0.20-0.66) | 0.55 (0.42-0.73) |
0.0 6 |
0.19 (0.12-0.31) |
0.41 (0.29-0.56) |
0.00 3 |
OS, overall survival; CI, confidence interval; EFS, event-free survival.